Compare Stocks: ADXN, TVRD, KPTI, and CLRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$3.16 +1.1%	$4.17	$2.56 ▼ $11.97	$3.86M	1.52	57,524 shs	5,386 shs
CLRB Cellectar Biosciences	$1.45 -4.2%	$2.33	$1.42 ▼ $5.07	$13.49M	0.58	381,637 shs	36,265 shs
KPTI Karyopharm Therapeutics	$0.61 -6.0%	$1.81	$0.60 ▼ $10.99	$13.74M	1.04	1.05 million shs	142,609 shs
TVRD Tvardi Therapeutics	$1.05 -5.0%	$1.70	$0.93 ▼ $43.65	$13.94M	0.38	822,061 shs	21,567 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-1.42%	+13.59%	-14.11%	-46.65%	-67.03%
CLRB Cellectar Biosciences	0.00%	-17.93%	-36.29%	-45.49%	-70.57%
KPTI Karyopharm Therapeutics	-0.75%	-47.13%	-63.97%	-93.68%	-88.82%
TVRD Tvardi Therapeutics	+1.85%	-12.00%	-42.41%	-71.05%	-97.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$3.16 +1.1%	$4.17	$2.56 ▼ $11.97	$3.86M	1.52	57,524 shs	5,386 shs
CLRB Cellectar Biosciences	$1.45 -4.2%	$2.33	$1.42 ▼ $5.07	$13.49M	0.58	381,637 shs	36,265 shs
KPTI Karyopharm Therapeutics	$0.61 -6.0%	$1.81	$0.60 ▼ $10.99	$13.74M	1.04	1.05 million shs	142,609 shs
TVRD Tvardi Therapeutics	$1.05 -5.0%	$1.70	$0.93 ▼ $43.65	$13.94M	0.38	822,061 shs	21,567 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-1.42%	+13.59%	-14.11%	-46.65%	-67.03%
CLRB Cellectar Biosciences	0.00%	-17.93%	-36.29%	-45.49%	-70.57%
KPTI Karyopharm Therapeutics	-0.75%	-47.13%	-63.97%	-93.68%	-88.82%
TVRD Tvardi Therapeutics	+1.85%	-12.00%	-42.41%	-71.05%	-97.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	628.48% Upside
KPTI Karyopharm Therapeutics	2.57	Moderate Buy	$11.50	1,682.95% Upside
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	1,536.36% Upside

Current Analyst Ratings Breakdown

Latest ADXN, TVRD, KPTI, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
10/2/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/24/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	TVRD Tvardi Therapeutics	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/27/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Negative
7/31/2026	KPTI Karyopharm Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
7/31/2026	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$3.00
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$13.00 ➝ $3.00

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$210K	18.36	N/A	N/A	$4.67 per share	0.67
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
KPTI Karyopharm Therapeutics	$146.07M	0.10	N/A	N/A	($16.00) per share	-0.04
TVRD Tvardi Therapeutics	$7.14M	2.06	N/A	N/A	$2.23 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-174.44%	-126.47%	11/9/2026 (Estimated)
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
KPTI Karyopharm Therapeutics	-$196.04M	-$13.09	N/A	N/A	N/A	-153.28%	N/A	-145.18%	11/2/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$2.79	N/A	N/A	N/A	N/A	-145.40%	-91.11%	N/A

Latest ADXN, TVRD, KPTI, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/2/2026	Q3 2026	KPTI Karyopharm Therapeutics	-$1.16	N/A	N/A	N/A	$33.54 million	N/A
9/25/2026	Q2 2026	ADXN Addex Therapeutics	N/A	-$1.48	N/A	-$1.48	N/A	$0.01 million
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	KPTI Karyopharm Therapeutics	-$1.37	-$2.32	-$0.95	-$2.32	$32.19 million	$33.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.76	0.76
CLRB Cellectar Biosciences	N/A	6.66	6.66
KPTI Karyopharm Therapeutics	N/A	0.79	0.76
TVRD Tvardi Therapeutics	N/A	1.87	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CLRB Cellectar Biosciences	16.41%
KPTI Karyopharm Therapeutics	66.44%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CLRB Cellectar Biosciences	2.58%
KPTI Karyopharm Therapeutics	1.68%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	3	1.23 million	1.05 million	Not Optionable
CLRB Cellectar Biosciences	11	9.45 million	9.21 million	No Data
KPTI Karyopharm Therapeutics	228	22.68 million	22.30 million	Optionable
TVRD Tvardi Therapeutics	80	13.34 million	12.35 million	N/A

ADXN, TVRD, KPTI, and CLRB Headlines

Recent News About These Companies

Tvardi Therapeutics (NASDAQ:TVRD) Stock Bumped Up to "Sell" by Wall Street Zen

October 4, 2026 | americanbankingnews.com

Tvardi Therapeutics (NASDAQ:TVRD) & Phibro Animal Health (NASDAQ:PAHC) Financial Contrast

October 1, 2026 | americanbankingnews.com

Forumsbeiträge zu Tvardi Therapeutics Inc. Registered shs

September 27, 2026 | finanzen.atF

Tvardi pubblica dati preclinici su inibitore STAT3 per la colite

September 25, 2026 | it.investing.com

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

September 25, 2026 | finance.yahoo.com

Tvardi Therapeutics, Inc. Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In Ulcerative Colitis

September 25, 2026 | marketscreener.comM

New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)

September 24, 2026 | globenewswire.com

Tvardi Therapeutics, Inc.(NasdaqCM:TVRD) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Tvardi Therapeutics Consensus Price Target Increased by 11.76% to $9.69

September 15, 2026 | msn.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

August 26, 2026 | globenewswire.com

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14, 2026 | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12, 2026 | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, TVRD, KPTI, and CLRB Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$3.16 +0.03 (+1.05%)

As of 11:14 AM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Cellectar Biosciences NASDAQ:CLRB

$1.45 -0.06 (-4.24%)

As of 11:17 AM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Karyopharm Therapeutics NASDAQ:KPTI

$0.61 -0.04 (-6.05%)

As of 11:17 AM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Tvardi Therapeutics NASDAQ:TVRD

$1.04 -0.06 (-5.00%)

As of 11:15 AM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADXN, TVRD, KPTI, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADXN, TVRD, KPTI, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADXN, TVRD, KPTI, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, TVRD, KPTI, and CLRB Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cellectar Biosciences NASDAQ:CLRB

Karyopharm Therapeutics NASDAQ:KPTI

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADXN, TVRD, KPTI, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADXN, TVRD, KPTI, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADXN, TVRD, KPTI, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, TVRD, KPTI, and CLRB Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cellectar Biosciences NASDAQ:CLRB

Karyopharm Therapeutics NASDAQ:KPTI

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools